Time for oncologists to opt in for routine opt-out HIV testing?

Area of Science:

• Oncology
• Infectious Diseases
• Public Health

Background:

• Individuals with human immunodeficiency virus (HIV) have an increased risk of developing malignancies.
• Routine HIV testing is not standard care for cancer patients, despite CDC recommendations for opt-out screening in all healthcare settings.
• Current opt-out HIV testing primarily targets specific populations, with limited implementation in broader clinical settings like oncology.

Purpose of the Study:

• To present the rationale and evidence supporting routine opt-out HIV testing for cancer patients.
• To discuss the potential of opt-out HIV testing to enhance clinical outcomes through improved HIV management during cancer treatment.

Main Methods:

• Review of background, rationale, and supporting evidence for opt-out HIV testing in cancer patients.
• Discussion of evidence for improved clinical outcomes via facilitated HIV management.

Main Results:

• Human immunodeficiency virus (HIV)-infected individuals are at high risk of malignancies.
• Routine opt-out HIV testing is not widely implemented in the United States, despite recommendations.
• Opt-out testing has shown potential in specific settings but requires broader application.

Conclusions:

• Routine opt-out HIV testing should be considered standard care for cancer patients.
• Implementing opt-out HIV testing can lead to better management of HIV during cancer treatment.
• This strategy has the potential to significantly improve clinical outcomes for HIV-positive cancer patients.